Thanks to lower-than-expected price, ICER backs Amgen's Aimovig—but only after other meds fail

Amgen and the Institute for Clinical and Economic Review have often clashed over drug prices, most recently after the cost watchdog said a new class of migraine meds would be a pricey burden on U.S. healthcare. But now that ICER has Amgen's official launch price for first-in-class Aimovig—a price several thousand dollars below expectations—it has endorsed the med's cost-effectiveness.